Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...
Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center
The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology...
Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories
Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to...
Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...
Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...
China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care
The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including...
Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors
Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...
Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...
Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines
Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...
Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued...
Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss
Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by...
Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator
01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly...
Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle
Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic...
IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis
China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...
MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...
NMPA Proposes Streamlined Market Approval Process for Domestically Produced Overseas Drugs
The National Medical Products Administration (NMPA) has released a draft proposal titled “Optimizing the Market...